CHronic RhINOSinusitis Outcome Registry (CHRINOSOR): establishment of an international outcome registry driven by mHealth technology.
Fiche publication
Date publication
octobre 2022
Journal
The journal of allergy and clinical immunology. In practice
Auteurs
Membres identifiés du Cancéropôle Est :
Pr JANKOWSKI Roger
Tous les auteurs :
Seys SF, Hellings PW, Alobid I, Backer V, Bequignon E, von Buchwald C, Cavaliere C, Coste A, Deneyer L, Diamant Z, Eckl-Dorna J, Fokkens WJ, Gane S, Gevaert P, Holbaek-Haase C, Holzmeister C, Hopkins C, Hox V, Huart C, Jankowski R, Jorissen M, Kjeldsen A, Knipps L, Lange B, van der Lans R, Laulajainen-Hongisto A, Larsen K, Liu D, Lund V, Mariën G, Masieri S, Mortuaire G, Mullol J, Reitsma S, Rombaux P, Schneider S, Steinsvik A, Tomazic PV, Toppila-Salmi SK, Van Gerven L, Van Zele T, Virkkula P, Wagenmann M, Bachert C
Lien Pubmed
Résumé
Real-world evidence (RWE) is a valuable instrument to better understand the patient journey and effectiveness of therapies. RWE on prevalence of uncontrolled CRS and CRS natural course of disease across Europe is scarce. In addition, there is limited RWE that enables comparison of effectiveness of marketed therapies including topical or systemic corticosteroids, sinus surgery or biologics.
Mots clés
biologic therapy, chronic rhinosinusitis, mobile health technology, nasal polyps, real-world evidence
Référence
J Allergy Clin Immunol Pract. 2022 10 19;: